Targeting CD73 to augment cancer immunotherapy-Reference-Cited by-同舟云学术

Targeting CD73 to augment cancer immunotherapy

Published:2020-08 Issue: Volume:53 Page:66-76
ISSN:1471-4892
Container-title:Current Opinion in Pharmacology
language:en
Short-container-title:Current Opinion in Pharmacology

Author:

Roh Meejeon,Wainwright Derek A^ORCID,Wu Jennifer D,Wan Yong,Zhang Bin

Funder

National Institutes of Health

Northwestern University

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology

Reference126 articles.

1. Ecto-enzyme and signaling functions of lymphocyte cd73;Resta;Immunol Rev,1998

2. Physiological roles for ecto-5’-nucleotidase (cd73);Colgan;Purinergic Signal,2006

3. Antibodies to 5’-nucleotidase (cd73), a glycosyl-phosphatidylinositol-anchored protein, cause human peripheral blood t cells to proliferate;Thompson;J Immunol,1989

4. Differential regulation and function of cd73, a glycosyl-phosphatidylinositol-linked 70-kd adhesion molecule, on lymphocytes and endothelial cells;Airas;J Cell Biol,1997

5. Cd73 expression and fyn-dependent signaling on murine lymphocytes;Yamashita;Eur J Immunol,1998

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Investigation of co-treatment multi-targeting approaches in breast cancer cell lines;European Journal of Pharmacology;2024-03

2. Mesenchymal stromal cells in myeloid malignancies: Immunotherapeutic opportunities;Heliyon;2024-02

3. miR-30b-5p targets CD73 and inhibits gastric cancer migration and invasion via PTEN/AKT/GSK3β/mTOR pathway;2024-01-25

4. CD73 contributes to the pathogenesis of fusion-negative rhabdomyosarcoma through the purinergic signaling pathway;Proceedings of the National Academy of Sciences;2024-01-16

5. Vdelta1 T cells are more resistant than Vdelta2 T cells to the immunosuppressive properties of galectin-3;Frontiers in Immunology;2024-01-08